Utilization of intravenous thrombolysis is increasing in the United States

International Journal of Stroke

Volumn 8, Issue 8, 2013, Pages 681-688

  Nasr, Deena M ^a   Brinjikji, Waleed ^a   Cloft, Harry J ^a   Rabinstein, Alejandro A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Acute stroke therapy; Epidemiology; Ischemic stroke; Neurology; rtPA; Socioeconomic factors

Indexed keywords

ALTEPLASE;

AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; COMORBIDITY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG FATALITY; DRUG SAFETY; DRUG UTILIZATION; FEMALE; FIBRINOLYTIC THERAPY; GENDER; HEART ATRIUM FIBRILLATION; HOSPITAL DISCHARGE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SENESCENCE; STROKE PATIENT; UNITED STATES;

ACUTE STROKE THERAPY; EPIDEMIOLOGY; ISCHEMIC STROKE; NEUROLOGY; RTPA; SOCIOECONOMIC FACTORS;

ADMINISTRATION, INTRAVENOUS; AGED; AGED, 80 AND OVER; COMORBIDITY; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; UNITED STATES;

EID: 84888094762     PISSN: 17474930     EISSN: 17474949     Source Type: Journal    
DOI: 10.1111/j.1747-4949.2012.00844.x     Document Type: Article

References (27)

1. Lansberg MG, Bluhmki E, Thijs VN. Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. Stroke 2009; 40:2438-2441.
2. Adeoye O, Hornung R, Khatri P, Kleindorfer D. Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years. Stroke 2011; 42:1952-1955.
3. Bambauer KZ, Johnston SC, Bambauer DE, Zivin JA. Reasons why few patients with acute stroke receive tissue plasminogen activator. Arch Neurol 2006; 63:661-664.
4. Alshekhlee A, Mohammadi A, Mehta S etal. Is thrombolysis safe in the elderly?: analysis of a national database. Stroke 2010; 41:2259-2264.
5. Di Carlo A, Lamassa M, Baldereschi M etal. Sex differences in the clinical presentation, resource use, and 3-month outcome of acute stroke in Europe: data from a multicenter multinational hospital-based registry. Stroke 2003; 34: 1114-1119.
6. Roquer J, Campello AR, Gomis M. Sex differences in first-ever acute stroke. Stroke 2003; 34:1581-1585.
7. Counsell C, Dennis M. Systematic review of prognostic models in patients with acute stroke. Cerebrovasc Dis 2001; 12:159-170.
8. Reid JM, Dai D, Gubitz GJ, Kapral MK, Christian C, Phillips SJ. Gender differences in stroke examined in a 10-year cohort of patients admitted to a Canadian teaching hospital. Stroke 2008; 39:1090-1095.
9. Gebhardt JG, Norris TE. Acute stroke care at rural hospitals in Idaho: challenges in expediting stroke care. J Rural Health 2006; 22:88-91.
10. Reed SD, Cramer SC, Blough DK, Meyer K, Jarvik JG. Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals. Stroke 2001; 32:1832-1840.
11. Johnston SC, Fung LH, Gillum LA etal. Utilization of intravenous tissue-type plasminogen activator for ischemic stroke at academic medical centers: the influence of ethnicity. Stroke 2001; 32:1061-1068.
12. Xian Y, Holloway RG, Chan PS etal. Association between stroke center hospitalization for acute ischemic stroke and mortality. JAMA 2011; 305:373-380.
13. Shobha N, Sylaja PN, Kapral MK, Fang J, Hill MD. Differences in stroke outcome based on sex. Neurology 2010; 74:767-771.
14. Machumpurath B, Davis SM, Yan B. Rapid neurological recovery after intravenous tissue plasminogen activator in stroke: prognostic factors and outcome. Cerebrovasc Dis 2011; 31:278-283.
15. Chen CI, Iguchi Y, Grotta JC etal. Intravenous TPA for very old stroke patients. Eur Neurol 2005; 54:140-144.
16. Tanne D, Gorman MJ, Bates VE etal. Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older: the tPA stroke survey experience. Stroke 2000; 31:370-375.
17. Mishra NK, Ahmed N, Andersen G etal. Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive. BMJ 2010; 341:c6046.
18. Ford GA, Ahmed N, Azevedo E etal. Intravenous alteplase for stroke in those older than 80 years old. Stroke 2010; 41:2568-2574.
19. Longstreth WT, Jr, Katz R, Tirschwell DL, Cushman M, Psaty BM. Intravenous tissue plasminogen activator and stroke in the elderly. Am J Emerg Med 2010; 28:359-363.
20. Mateen FJ, Nasser M, Spencer BR etal. Outcomes of intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 90 years or older. Mayo Clin Proc 2009; 84:334-338.
21. Divani AA, Vazquez G, Asadollahi M, Qureshi AI, Pullicino P. Nationwide frequency and association of heart failure on stroke outcomes in the United States. J Card Fail 2009; 15:11-16.
22. Bateman BT, Schumacher HC, Boden-Albala B etal. Factors associated with in-hospital mortality after administration of thrombolysis in acute ischemic stroke patients: an analysis of the nationwide inpatient sample 1999 to 2002. Stroke 2006; 37:440-446.
23. Mustanoja S, Meretoja A, Putaala J etal. Outcome by stroke etiology in patients receiving thrombolytic treatment: descriptive subtype analysis. Stroke 2011; 42:102-106.
24. Lansberg MG, Albers GW, Wijman CA. Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors. Cerebrovasc Dis 2007; 24:1-10.
25. Kent DM, Selker HP, Ruthazer R, Bluhmki E, Hacke W. The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke. Stroke 2006; 37:2957-2962.
26. Kleindorfer D, Lindsell CJ, Brass L, Koroshetz W, Broderick JP. National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate. Stroke 2008; 39:924-928.
27. Qureshi AI, Harris-Lane P, Siddiqi F, Kirmani JF. International classification of diseases and current procedural terminology codes underestimated thrombolytic use for ischemic stroke. J Clin Epidemiol 2006; 59:856-858.